Immunovant, Inc. (NASDAQ:IMVT) CTO Jay S. Stout Sells 2,740 Shares of Stock

Immunovant, Inc. (NASDAQ:IMVT) CTO Jay S. Stout sold 2,740 shares of the firm’s stock in a transaction on Wednesday, October 23rd. The stock was sold at an average price of $29.53, for a total value of $80,912.20. Following the completion of the sale, the chief technology officer now directly owns 142,186 shares of the company’s stock, valued at approximately $4,198,752.58. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Immunovant Stock Down 0.9 %

NASDAQ IMVT opened at $30.22 on Friday. The company has a 50 day moving average price of $30.07 and a two-hundred day moving average price of $28.94. Immunovant, Inc. has a 12-month low of $24.67 and a 12-month high of $45.58. The stock has a market capitalization of $4.42 billion, a PE ratio of -15.66 and a beta of 0.66.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.07). During the same period in the previous year, the company posted ($0.57) EPS. As a group, equities analysts anticipate that Immunovant, Inc. will post -2.41 EPS for the current year.

Institutional Trading of Immunovant

Several large investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in shares of Immunovant by 75.0% in the 4th quarter. Wellington Management Group LLP now owns 295,020 shares of the company’s stock valued at $12,429,000 after acquiring an additional 126,412 shares in the last quarter. Allspring Global Investments Holdings LLC raised its position in shares of Immunovant by 51.9% in the first quarter. Allspring Global Investments Holdings LLC now owns 65,091 shares of the company’s stock valued at $2,103,000 after purchasing an additional 22,226 shares during the period. Principal Financial Group Inc. raised its position in shares of Immunovant by 32.4% in the first quarter. Principal Financial Group Inc. now owns 582,721 shares of the company’s stock valued at $18,828,000 after purchasing an additional 142,606 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Immunovant by 98.3% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 71,788 shares of the company’s stock worth $2,319,000 after buying an additional 35,589 shares during the last quarter. Finally, Sei Investments Co. boosted its holdings in shares of Immunovant by 11.2% during the 1st quarter. Sei Investments Co. now owns 20,690 shares of the company’s stock worth $668,000 after buying an additional 2,085 shares during the period. Institutional investors own 47.08% of the company’s stock.

Wall Street Analyst Weigh In

IMVT has been the subject of several research analyst reports. JPMorgan Chase & Co. reduced their price objective on Immunovant from $51.00 to $46.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. UBS Group dropped their target price on Immunovant from $42.00 to $41.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th. HC Wainwright restated a “buy” rating and set a $51.00 price target on shares of Immunovant in a report on Monday, September 30th. Raymond James reaffirmed an “outperform” rating and set a $36.00 price objective on shares of Immunovant in a research report on Thursday, October 10th. Finally, Oppenheimer increased their target price on shares of Immunovant from $47.00 to $53.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 9th. Eleven analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $48.10.

About Immunovant

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.